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Abstract
The last decade has been a frustrating time for investigators who had envisioned major advances in the treatment of Parkinson’s
disease using neurotrophic factors. The first trials of glial cell line–derived neurotrophic factor for treating Parkinson’s disease
were very promising. Later blinded control trials were disappointing, not reaching the predetermined outcomes for improvement
in motor function. Consideration of the problems in the studies as well as the biology of the neurotrophins used can potentially
lead to more effective therapies. Parkinson’s disease presents a multitude of opportunities for the cell biologist wanting to
understand its pathology and to find possible new avenues for treatment.
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Introduction: Parkinson’s disease and how
cell biology can help
Parkinson’s disease presents a multitude of opportunities for
the cell biologist wanting to understand its pathology and to
find possible new avenues for treatment. As pointed out in a
recent review, Parkinson’s disease is a neurological disorder
with evolving layers of complexity (see Kalia and Lang 2015
for an excellent clinical summary). The most easily recog-
nized aspects of the disease are the motor signs of slow move-
ment, muscle rigidity, tremor, and postural instability. These
are associated with loss of dopaminergic neurons in the
substantia nigra and the accumulation of Lewy bodies com-
posed of synuclein in nerve cells. Nonmotor symptoms such
as constipation and depression predate clinical motor signs
and then, late in the disease, cognitive disabilities increase.
These changes are due to non-dopaminergic cell damage.
Dopamine replacement works dramatically for the initial mo-
tor deficiencies and a strong positive response helps to make
the diagnosis of the disease. Unfortunately, as the disease
progresses, this treatment becomes less effective and produces
major side effects. Deep brain stimulation can significantly
improve motor symptoms and reduce some of the side effects
of oral drug treatment, but it does not change the course of the
disease.
The complexity of the signs and symptoms of Parkinson’s
disease is mirrored by the complexity of the many environ-
mental and genetic factors that have been shown to be associ-
ated with its development. The growing list of environmental
factors that increase risk, such as pesticide exposure, head
injury, and rural living, is matched by the enlarging number
of genetic risk factors that have been discovered. A few iden-
tified genes put patients at high risk for developing the disease
and have been tied to its physiology. However, in the vast
majority of sporadic cases, 90% plus, genetic causes have
not been found or have a very small association (Kalia and
Lang 2015).
An example of the importance of novel cell biology ap-
proaches for finding new treatments is the recent work on
induced pluripotent stem cells (iPSCs) that can be directed
into dopaminergic cell types. Using such cells taken from
Parkinson patients with the sporadic form, no definitive ge-
netic abnormalities were demonstrated. However, these nega-
tive findings are not true for the 10% of sporadic cases of
young-onset Parkinson’s disease, ages 21 to 50 (Laperle
et al. 2020). Dopaminergic iPSCs generated from these youn-
ger patients show increases in synuclein and phosphorylated
protein kinase C alpha and reduced levels of liposomal mem-
brane proteins such as LAMP1. So far, unidentified genetic
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factors are clearly important in the group of sporadic patients
who have early disease, and the results point to an early mark-
er. The investigators found that specific phorbol esters reverse
these changes in levels and suggest a new physiologically
based approach to early treatment (Laperle et al. 2020).
Thus, applying cell biology knowledge and methods in this
patient group led to the identification of an early marker of the
disease, as well as providing clues as to how it might be
treated before clinical symptoms become apparent.
The cell biology of GDNF family ligands
and clinical trials
Cell biology approaches have been central to the effort to use
glial cell line–derived neurotrophic factor (GDNF) family li-
gands to treat Parkinson’s disease. GDNFwas originally iden-
tified in a screen for factors with the capacity to increase the
uptake of dopamine in an in vitro assay (Lin et al. 1993).
Importantly, GDNF was from the very beginning found to
support the survival of midbrain dopaminergic neurons
(Lin et al. 1993). Three years later, RET (rearranged during
transfection) was identified as a tyrosine kinase transmem-
b r ane r e c ep t o r , wh i ch i n t h e p r e s ence o f t h e
glycosylphosphatidylinositol (GPI)–linked co-receptor
GFRa1 (GDNF family receptor alpha 1) mediates GDNF-
dependent signaling (Durbec et al. 1996; Jing et al. 1996;
Treanor et al. 1996; Trupp et al. 1996). More recently, studies
with conditional knock-out mice demonstrated that
parvalbumin neuron-derived GDNF maintains dopaminergic
neurons in the adult brain (Enterria-Morales et al. 2020). The
first trials of GDNF for Parkinson’s disease were very prom-
ising. Later blinded control trials were disappointing, not
reaching the predetermined outcomes for improvement in mo-
tor function (Bartus and Johnson Jr 2017a, b; Gash et al.
2020). Consideration of the problems in the studies as well
as the biology of the neurotrophins used can potentially lead to
more effective therapies.
GDNF family ligand signaling
A wide range of knowledge on the ligand/receptor complex
has been gathered covering homologs, co-receptors, expres-
sion patterns, regulatory elements, biological functions, and
results from clinical trials (Airaksinen et al. 2006; Goodman
et al. 2014; Ibáñez and Andressoo 2017; Kirkeby and Barker
2019).
To understand what can be done, a brief outline of the
signaling complex is essential. As to ligand specificity and
receptor complex formation, we now know that four homolo-
gous GDNF family ligands can activate RET-signaling via
four homologous GPI-linked co-receptors. While GDNF
signals via GFRa1 (Treanor et al. 1996), neurturin (NRTN)
signals via GFRa2, artemin (ARTN) via GFRa3, and
persephin (PSPN) via GFRa4 (for a review see Airaksinen
and Saarma 2002). Moreover, evolutionarily distant GDF15/
GRAL can also activate RET (Hsu et al. 2017). While all co-
receptors can interact with RET, ligand specificity is mediated
via differential affinity of the ligands to the co-receptors.
However, it is worth noting that cross signaling has also been
reported. GDNF can signal via GFRa2 and NRTN via GFRa1
(Buj-Bello et al. 1997; Wang et al. 2000). Furthermore, it is
also worth noting that membrane-bound GPI-linked co-
receptors can be cleaved off and mediate signaling as soluble
co-receptors (Fleming et al. 2015; Wang et al. 2000). Thus, in
the presence of soluble co-receptors, GDNF family ligands
can active RET also in cells which lack endogenous co-
receptor expression. The crystal structures of GDNF/GFRa1
(Parkash et al. 2008), NRTN/GFRa2 (Sandmark et al. 2018),
and ARTN/GFRa3 (Wang et al. 2006) complexes have been
solved. Even the structures of the full GDNF/GFRa1/RET and
NRTN/GFRa2/RET complexes have been resolved using a
combination of electron microscopy and low-angle X-ray
scattering (Goodman et al. 2014), or cryo-EM (Bigalke et al.
2019).
Issues in the clinical trials
Dopamine augmentation versus disease progression
Unfortunately, none of the current medical or surgical thera-
pies for Parkinson’s disease significantly alters the course of
the disease (Kalia and Lang 2015). L-Dopa medication and
deep brain stimulation (DBS) definitely help symptoms but do
little or nothing about the progression of the pathology.
Furthermore, even the best current treatments do not restore
patients to their normal function. Quantitative measures of
voluntary movements demonstrate that by the time mild dis-
ease is detected; movement speed has been slowed by 50% or
more (Pfann et al. 1998). Treatment with dopaminergic med-
ications makes patients feel and perform better and modestly
improves movement speed, but it never returns to normal
(Vaillancourt et al. 2004). In later stage disease, DBS subtha-
lamic nucleus stimulation does produce major improvements,
i.e., a 50% change in the United Parkinson’s Disease Rating
Scale, and it significantly decreases tremor and dyskinesias.
However, even in this case, movement speeds do not return to
normal (Vaillancourt et al. 2004). Current theories of how
subthalamic nucleus works recognize that stimulation does
not increase normal functioning but reduces the abnormal sig-
nals coming out of the damaged basal ganglia circuits (Chiken
and Nambu 2016). Subthalamic nucleus stimulation, like a
lesion, regularizes globus pallidus output but does not return
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the system to its previous functional state (Humphries and
Gurney 2012; Humphries et al. 2018).
The course of the disease is marked by a progressive loss of
dopaminergic neurons, and thereby, there is an urgent need to
identify new treatments which support the survival of these
neurons. However, when evaluating the outcome of such tri-
als, it is clear that we need to distinguish between a short-term
boost of dopaminergic function providing symptomatic relief,
from a long-term protective effect reducing cell death. It is the
latter that ultimately will be necessary for a clinically impor-
tant disease effect.
These biological considerations of Parkinson’s disease
mean that human studies have to be powered to find a differ-
ence in disease progression and dopamine augmentation
which produces only symptomatic relief. As with
Alzheimer’s disease, studies may need to be done early in
disease development and include longer follow-up. Such
study designs are slow, time-consuming, and expensive.
Dissecting out changes in symptoms versus the slowing of
progression is especially hard when the biological changes
due to a neurotrophic factor occur over months.
Unmet endpoints versus promising observations
The last decade has been a frustrating time for investigators
who had envisioned major advances in the treatment of
Parkinson’s disease using neurotrophic factors. In spite of
very encouraging proof of principle studies, demonstrating a
marked improvement in symptoms with NRTN delivered by
viral injection, and glial-derived neurotrophic factor (GDNF)
infused into the putamen, controlled clinical trial did not
achieve a large enough change in motor performance to reach
a significant statistical outcome (Gash et al. 2020).
A larger than anticipated placebo response was seen in all
the studies. This could be due to placebo effects, bias on the
part of raters, or the implantation of a large catheter into the
putamen. Postoperative observations indicate that inserting a
DBS electrode, which is similar in size to a catheter, into the
subthalamic nucleus often results in clinical improvement for
days to weeks. The effects of catheter placement and saline
infusions are not fully tested. However, the 40-week saline
control infusion used in the latest GDNF study patients
showed an improvement of off time motor function of 15%.
The authors speculate that the implantation and bolus infu-
sions might be the cause of this “placebo effect” (Whone
et al. 2019a, b). A study in non-human primates showed a
similar improvement in motor function in the control group
being infused with saline (Gash et al. 2005).
A number of important positive results from the clinical
trials have been pointed out (Kirkeby and Barker 2019).
Autopsy findings in patients who died from other causes show
dopaminergic nerve fibers streaming towards the catheter po-
sitioned in the putamen with infused GDNF. This indicates a
strong trophic influence on the dopamine cells. Furthermore,
f-Dopa turnover significantly increases in the region surround-
ing the catheter infused tip. This was true even though clinical
responses did not reach significance. In the latest placebo-
controlled GDNF trial, all of the treatment measurements dur-
ing the blinded period and follow-up are better than those of
the untreated patients suggesting a true change (Whone et al.
2019b). Analysis of the NRTN study also showed significant
improvement in patients treated early in the disease. Other
signs of efficacy are found in the two original trials that were
done in the USA andUK (Slevin et al. 2007; Gash et al. 2020).
Both showed dramatic responses in motor function. In many
of these patients, the effect lasted several years after the infu-
sion of GDNF was stopped. Variability in the delivery of the
neurotrophic across studies and individual variation within
studies may explain why it is been so difficult to demonstrate
efficacy.
Human disease versus animal models
The most straightforward explanation for the failed clinical
trials is that GDNF family ligands do not rescue and maintain
dopaminergic neurons when used for the human disease, even
though they perform well in animal models. Compared with
the chemically induced animal disease models, the pathobiol-
ogy of the human disease is clearly different, and it should not
be a surprise that the response is different. In the primate 1-
methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) model,
loss of dopamine input is immediate and nearly complete,
and the treatment starts as soon as the neurological deficit
has stabilized, soon after the lesion. In the human disease,
dopaminergic neurons are gradually lost over many decades
and clinical diseases are only recognized after 50% or more of
neurons are lost. This slow progression leads to a gradual
transformation in basal ganglion pathways. The brain is dras-
tically altered morphologically and functionally even before
Parkinson’s disease is diagnosed and a therapeutic interven-
tion began. An example of the change is that a lesion, such as a
stroke, in the subthalamic nucleus that would cause wild dys-
kinetic movements in a normal individual, has the opposite
effect on a patient with Parkinson’s disease. A lesion in the
damaged subthalamic nucleus or globus pallidus internal seg-
ment decreases abnormal dyskinetic movements (Pfann et al.
1998). The later the treatment of Parkinson’s disease, the more
altered are basal ganglia neurons and their connections and the
less likely that pathological will be reversed by therapeutic
interventions.
In addition to the animal models which are based on chem-
ical induction, there are animal models which are based on the
replication of familial Parkinson’s disease mutations. Many of
the symptoms covered by the United Parkinson’s Disease
Rating Scale are difficult to evaluate in non-human species.
While one animal model may replicate one kind of symptoms
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of Parkinson’s disease, another animal model may replicate
other types of symptoms (Konnova and Swanberg 2018).
Even in humans, Parkinson’s disease is a heterogeneous dis-
ease with variations in the age of onset, symptoms, and rate of
progression. From a cell biology point of view, it is thereby
essential but challenging to understand what cell types to tar-
get and what types of cellular functions to support.
Different types of neurons are interconnected in a complex
network, but also different types of glial cells support essential
functions in this network. GDNF has primarily been adminis-
tered to the putamen to support dopaminergic fibers with cell
bodies located in substantia nigra (Ai et al. 2003). GDNF was
originally identified as a growth factor supporting mouse em-
bryonic midbrain dopaminergic neurons (Lin et al. 1993), and
the expression of its receptors GFRa1 and RET has been ver-
ified not only in the putamen of elderly human adults but also
in the putamen of patients with Parkinson’s disease (Bäckman
et al. 2006). Also, GFRa2 has been detected in human
substantia nigra, globus pallidus, and putamen (Runeberg-
Roos et al. 2016). However, it would be valuable to know if
the expression of the receptor complex differs between pa-
tients with varying genetic backgrounds and at various stages
of the disease. For GDNF trials, it would be essential to estab-
lish that the signaling mediating receptor complex (RET and
GFRα receptors) is expressed in the targeted cell types, in all
patients selected for trials.
The importance of accurate drug delivery
Neurotrophin delivery should ideally be to the specific regions
having cells that respond and have limited spill over into other
regions. Such delivery would maximize positive clinical ef-
fects and minimize adverse side effects. In practice, this is
difficult to achieve because of the morphology of target re-
gions, somewhat kidney-shaped in the case of the putamen,
and the anisotropic nature of brain tissue. The delivery prob-
lem is made more difficult by the relatively large size of neu-
rotrophic factors and their limited diffusion in the extracellular
space.
The putamen has been the target of choice in Parkinson’s
disease because dopaminergic fibers flow into this region
where cellular uptake occurs in the widely distributed pre-
synaptic dopaminergic projections. Uptake and then retro-
grade movement allow the factors to be carried to the cell
bodies in the substantial nigra in the midbrain. Experiments
have looked at distribution from single and multiple needle
injection sites in the putamen, slow infusion from catheters, or
convection-enhanced delivery which injects large volumes of
fluid with enough pressure to cause convective flow in the
tissue in the extracellular spaces.
A number of important conclusions can be drawn from the
decades of work on this problem. The first and foremost is that
the effect of an injected neurotrophin depends on the volume
of the target area that is covered. As Gash’s group has clearly
demonstrated for GDNF injections in a non-human primate
model of Parkinson’s disease, the amount of improvement
motor performance measured by a clinical motor rating scale
is directly related to the volume covered (Table 1). In a later
study using precisely the same implanted drug pump, catheter
system and infusion protocol as in the Amgen double-blind
study, a fourfold variation in the volume covered, 87 to
369 mm, was observed (Salvatore et al. 2006). The system
used for delivery did not work uniformly; it delivered different
amounts of drug in each animal.
There is also the problem of scaling up to the much larger
human brain. Since the human putamen is 4000 to 5000 mm,
five times the size of the monkey, the infusion would be ex-
pected to cover only 2 to 9% of its volume (Yin et al. 2009).
This certainly calls into question whether or not GDNF helps
was tested adequately in the Amgen trial (Fan et al. 2015).
To overcome some of the delivery problems of large ther-
apeutic molecules, convection-enhanced infusions have been
employed in both animal and human trials. Normally, distri-
bution of a molecule in the extracellular space is ruled by
diffusion down to its concentration gradient and is inversely
related to its size. If the molecule is introduced under enough
fluid pressure and sufficient volume, flow becomes convec-
tive in the extracellular space and can carry both large and
small molecules much longer distances in less time (Lonser
et al. 2015). Such an approach was used in one of the first
open trials of GDNF and produced uniformly positive clinical
results (Slevin et al. 2005). Unfortunately, this convection-
enhanced protocol was not used for the Amgen controlled
trial, and it is likely that the distribution was very limited as
the non-human primate study showed (Salvatore et al. 2006).
Another important aspect of any delivery is the diameter of
the catheter or needle used. Larger diameters allow fluid to
escape along the pathway from the tip of the catheter along the
outside of tubing into the CSF spaces over the brain. A further
problem with delivery is the infusion of drug near a large
blood vessel and its perivascular space. Fluid flow in
perivascular spaces is rapid and would dominate as a sink
for the molecules that are being delivered near to it. Such
vessels cannot be seen on imaging studies and thus cannot
be avoided.
The technical ability of the surgeon to correctly position the
catheter adds still another level of variability to the trials.
Placement precision has improved greatly over time, but small
errors could potentially affect delivery. For example, if the
delivery is near the adjacent white matter tracks along the
putamen which conduct fluid easily, the infusion fluid could
be lost and not reach its target site (Linninger et al. 2008). The
recent study in Parkinson’s disease use contrast agents to de-
termine the distribution of infused fluid (Whone et al. 2019a).
The caveat is that the agent used may distribute differently
than the neurotrophic factor.
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Diffusion in brain tissue and modified GDNF family
ligands
While the distribution of a neurotrophic factor is critically
dependent on where and how it is delivered, it also is depen-
dent on its binding in the extracellular space. Early experi-
ments demonstrated that the distribution of GDNF in the ex-
tracellular space is limited by its heparin-binding sites. Co-
administration of GDNF and heparin dramatically increase
its distribution, but heparin cannot be used in the human clin-
ical trials because of the danger of hemorrhage (Hamilton
et al. 2001). The distribution of NRTN in the extracellular
space is even more limited, due to its higher heparin-binding
properties (Hadaczek et al. 2010). The human putamen is five
times bigger than in rhesus monkeys that are tested preclini-
cally for a response to a neurotrophin (Yin et al. 2009). It is
critically important to ensure that the infused GDNF protein or
virally expressed NRTN protein diffuses readily so that in
human trials, enough of the much of the larger putamen is
covered.
The structures of the ligands need to be described in order
to determine how to achieve a wider distribution in the extra-
cellular space. GDNF family ligands are dimeric ligands with
seven S-S bridges (Eigenbrot and Gerber 1997; Parkash et al.
2008; Sandmark et al. 2018; Wang et al. 2006). Six of the
bridges are intramolecular, while one is intermolecular, cova-
lently connecting the two monomers. The structure of each
monomer has been depicted as a pair of protruding fingers,
connected via a hinge (alpha helix). Each monomer interacts
with a GFRa receptor via the tips of the fingers (Parkash et al.
2008; Sandmark et al. 2018; Wang et al. 2006). In dimers,
there are two pairs of fingers, which drive the dimerization
of the receptor complex. While the tips of the fingers have
been shown to drive the dimerization of the receptor complex,
the alpha helix has been described as a flexible hinge, with no
direct interactions with the receptors.
The structure of GDNF is special in the sense that it harbors
an extra protrusion at the N-terminus, before the first ligand-
binding finger. Heparin-binding sites have been identified in
this N-terminal protrusion (Alfano et al. 2007), and to improve
the poor bio-distribution of GDNF, an N-terminally truncated
version of GDNF was engineered. This variant of GDNF
retained the ability to activate the receptor complex, showing
a 1.5–1.9-fold increased distribution in rat brains, but was not
more efficient than GDNFwt in a 6-OHDA rat model of PD
(Smith et al. 2015). Further non-human primate studies with
rhesus macaques indicated that the distribution volume of this
GDNF variant exceeded the distribution of GDNF wild type
by more than 2-fold and that it also increased dopamine turn-
over similarly to GDNF wildtype (Grondin et al. 2019).
As NRTN harbors potential heparin-binding sequences
within the hinge which connects the two ligand-binding fin-
gers (Fig. 1), it was a natural target for engineering a NRTN
variant with reduced binding to heparin (Runeberg-Roos et al.
2016). In three of the engineered NRTN variants, point muta-
tions were introduced in the helix sequence. In the fourth
variant, the hinge region of NRTN was substituted with the
corresponding hinge region from PSPN. The PSPN hinge was
chosen because this GDNF family ligand is highly homolo-
gous to NRTN but has a very low affinity for heparin (Alfano
et al. 2007; Bespalov et al. 2011). This straightforward engi-
neering approach resulted in a NRTN variant with retained
receptor activating capacity, and a 4-fold increased spreading
in tissue (Fig. 2). Needless to say, when deleting potential
heparin-binding sites from a ligand to make it diffuse more
readily, one must make sure that the biological activity, i.e.,
receptor-binding capacity of the ligand is not impaired. The
activity of the NRTN variant N4 was first characterized in
cell-based receptor affinity assays, dose-dependent RET-phos-
phorylation assays, and in vitro survival assays on dopaminer-
gic neurons from mouse midbrains and mouse embryonic kid-
ney cultures. Finally, in a 6-hydroxydopamine rat model of
Parkinson’s disease, N4 improved the conditions of the animals
more potently than GDNF (Runeberg-Roos et al. 2016).
Biological activity and prokaryotic versus eukaryotic
source of the protein
Clinical trials are naturally planned by medical doctors and
pharmacists who have the required solid knowledge on rigor-
ous regulations, complex clinical data, and advanced surgery
technology. Although the source of GDNF is just one out of a
myriad of components of the trial, its quality is essential for
the outcome of the trial. Mammalian GDNF is a glycosylated
dimeric protein with seven S-S bridges. In mammalian cells,
all secreted proteins are normally subjected to a strict mam-
malian protein quality control, which ensures a correct folding
of the protein. A correct folding is important for both proteo-
lytic stability and biological activity of the secreted protein.
The only preparation of GDNF that has been available for
clinical trials is by now over two decades old. This version
of GDNF was produced without S-S bridges and glycosyla-
tion in Escherichia coli, using purification procedures that
generally include denaturation/renaturation steps. NRTN and
GDNF have been shown to bemore stable when purified from
Table 1 Data adopted from Fig. 5A in Gash et al. (2005), showing a
significant correlation between improvement score of motor function
(non-human primate rating scale, mean of weeks 4–10), and the volume
of GDNF distribution in rhesus monkeys with MPTP lesions
GDNF diffusion in rhesus
monkeys (mm3)
Improvement score of
motor function
100 1.5
200 2.7
300 3.5
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Fig. 2 Spreading of WT NRTN in rat brains 24 h after infusion (a–c),
compared with the spreading of the modified NRTN variant N2 (d–f) and
the modified NRTN variant N4 (g–i). Vertically, the panels in the middle
represent sections at the injection site (AP, + 1.0), while sections 1 mm
from the injection site are shown to the left (AP, + 2.0) and right (AP, +
0.0). Scale bar 7 mm. With permission from Elsevier, original figure
published in Runeberg-Roos et al. (2016)
Fig. 1 Model of a NRTN dimer,
with finger-like structures con-
nected via a helix (heel). The be-
ginning (V45) and end (R56) of
the helix are shown with arrows.
The location of mutated amino
acids is shown in blue and red.
With permission from Elsevier,
original figure published in
Runeberg-Roos et al. (2016)
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mammalian cells (Hoane et al. 2000; Piccinini et al. 2013) and
more stable ligands naturally have a higher capacity to activate
receptor complexes. Using a mammalian source of GDNF for
clinical trials would ensure that the trials are done with a high
quality of the therapeutically active ingredient.
In the case of viral delivery of GDNF or NRTN, the protein
is indeed synthesized and secreted from the patient’s own
cells. As with all other technology, the viral delivery of li-
gands has its own pitfalls. In mammalian cells, endogenous
preproNRTN is synthesized at low concentrations with an N-
terminal presequence which targets the protein into the endo-
plasmic reticulum for secretion. The presequence is cleaved
off as soon as the protein passes the ERmembrane. The role of
the prosequence of NRTN has remained elusive, but
prosequences are in general thought to assist folding, or steri-
cally hinder the secreted protein from being active before se-
cretion. Prosequences are in general cleaved off before the
protein is secreted out of the cell. In the case of NRTN, it is
thought that only mature NRTN, lacking the prosequence, is
secreted. For viral delivery of NRTN in clinical trials, the
endogenous prosequence of NRTN was replaced by the
prosequence from NGF (Gasmi et al. 2007).
For unknown reasons, overexpressed preproNRTN is poorly
secreted from mammalian cells (Fjord-Larsen et al. 2005) and
purified mature NRTN (lacking preprosequences) is a tricky
protein which must be handled with great care to avoid aggre-
gation upon buffer exchanges or concentration (unpublished).
Therefore, from a protein chemistry point of view, there are
good reasons to carefully plan the design of viral delivery of
NRTN. A viral vector which drives a high expression of human
NRTN may lead to the aggregation of NRTN inside the endo-
plasmic reticulum, which potentially could hinder NRTN se-
cretion and trigger unfolded protein response, or even cell
death. High expression levels of NRTN may also lead to the
secretion of partially monomeric NRTN (unpublished), and
monomers of NRTNmay even inhibit activation of the receptor
complex. In clinical trials, the ligand is delivered over long
periods of time, so it would be important to make sure that it
is secreted as an active dimeric protein, and is not aggregating,
subsequently causing endoplasmic reticulum stress and mal-
function of the cells which secrete the protein.
Protein infusion versus viral expression
Neurotrophic factors which could support the survival of neu-
rons, and thereby slow the course of the disease, are proteins
which do not pass the BBB. Therefore, their use has so far
been dependent on a direct intracranial delivery. This type of
delivery is challenging not only from a surgery point of view
but also from a protein chemistry point of view. Normally,
biological activity of neurotrophic factors is achieved via cel-
lular secretion of very low concentrations of these factors into
the extracellular matrix.
GDNF delivery via direct protein infusions has several
clear advantages. The dose can be controlled and changed
during the course of treatment, the delivery can be stopped
at any point, and in theory, even the co-receptor soluble
GFRa1 could easily be co-infused. For therapeutic use,
GDNF has been dissolved into a synthetic buffer (NaCitrate/
NaCl) before infusion into the brain. The pI value of GDNF is
high, so a weakly acidic buffer ensures a positive charge of the
protein and thereby protects it from aggregation. From a pro-
tein chemistry point of view, the injection of the protein into
the brain is comparable with a type of buffer exchange. Buffer
exchanges are known as hurdles in protein chemistry. They
can cause protein aggregation and inactivation, especially if
the concentration of the infused protein is high. In part of the
clinical trials, the doses of infused GDNF were up to 14 or
30 μg/day (Gill et al. 2003; Slevin et al. 2005), which could
create technical difficulties. Systematic characterization of
how the activity is affected by different infusion buffers, dif-
ferent concentrations of the infused protein, and various
speeds of infusion could solve such problems.
Delivery via viral vectors has the clear advantage that the
treatment is achieved via one single surgery. A potential ad-
ditional advantage is that the expression can be directed to
take place only in selected cells, which might mimic a more
natural distribution of the ligand inside the tissue. Although
the viral vector can not be withdrawn, there is hope that the
expression level of the ligand can be regulated via systemic
delivery of small-molecule drugs which would keep the ex-
pression levels at desired levels (Chtarto et al. 2016).
However, it is clear that this type of regulation of the concen-
tration of the secreted protein requires an extra level of tech-
nical knowledge, including for instance mastering of leaking
promotors as well as the challenge of differential responsivity
of different cell types. It should also be kept in mind that part
of the inducible vectors drives high expression level when
turned on, so even though they would be turned off for periods
of time, the protein produced during the boosts of high expres-
sion may not be of high quality.
Low doses versus high doses
Normal concentrations of GDNF in tissue are in the range of
4 pg/mg (Chtarto et al. 2007), and 1–5 ng/ml of GDNF has
been shown to induce activation of RET in vitro (Yang et al.
2004; Runeberg-Roos et al. 2016). The average volume of the
whole human brain is 1500 cm3. This means that if GDNF
could diffuse freely and would not be subjected to proteolytic
degradation, as low a dose as 1.5–7.5 μg would be enough to
activate receptor complexes throughout the whole human
brain. Moreover, in the clinical trials, the goal has been to
target striatum which is only 7 cm3, so for this purpose, only
7–35 ng of GDNF would be needed. In clinical trials, the dose
has been more than 10 μg/putamen/day (Gill et al. 2003;
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Slevin et al. 2005), which means that GDNF has been used in
excess. There are probably several reasons behind the use of
these high amounts of GDNF: one is that after injection, it
attaches to the extracellular matrix, which hinders an efficient
spreading from the injection site, and another is that the ligand
is degraded by proteolytic enzymes.
However, high local concentrations of the ligand may be
contra-productive if the high concentrations induce an aggre-
gation of the protein already upon injection into the tissue.
Another more theoretical but still relevant argument against
excess amounts of the ligand is based on the available struc-
tural data on the ligand/receptor complex. GDNF is a dimeric
ligand, which binds two GFRa1 co-receptors and this ternary
complex dimerizes and activates two transmembrane tyro-
sine kinase receptors RET. In theory, a too high concentra-
tion of the dimeric ligand can saturate all available GFRa1
co-receptors to the extent that no ternary GDNF/GFRa1
complexes can form (the only formation of trimeric com-
plexes, consisting of dimeric GDNF bound to one GFRa1
co-receptor). In such a situation, the high concentrations of
GDNF would de facto inhibit the dimerization and activation
of RET.
Therefore, it would be safer to work with low doses of the
ligand and instead modify the ligand to achieve both a higher
resistance to proteolytic degradation, as well as a lower affin-
ity for the extracellular matrix. In the previously mentioned
GDNF variant with reduced heparin-binding, a few amino
acid substitutions were indeed introduced with the specific
aim to improve the chemical stability of GDNF (Smith et al.
2015). As already mentioned, the N4 variant of NRTN was
originally designed to decrease its heparin-binding capacity.
Importantly, it is also worth noting that this variant turned out
to be less prone to aggregation during purification. In addition,
using a kidney in vitro organogenesis assay, we found that its
higher biological activity was due to its higher resistance to
proteolytic degradation (Runeberg-Roos et al. 2016).
Protein engineering is a powerful tool, which in the context
of diabetes has been used to produce both fast- and long-
acting insulin variants for themarket. In the context of obesity,
a long-acting variant of GDF15 was engineered, produced,
and successfully tested in animal trials (Xiong et al. 2017).
Protein engineering should be considered as an option to im-
prove the effect of the GDNF family ligands for Parkinson’s
disease. Two separate groups have already successfully com-
pleted protein engineering and subsequent animal trials with
variants of GDNF (Smith et al. 2015) or NRTN (Runeberg-
Roos et al. 2016). In both cases, the results show improved
bio-distribution and increased stability. In the case of the
NRTN variant, testing in the MPTP primate model showed
enhanced biological and behavioral effects (manuscript in
preparation).
New directions
Making surgical lesions in the basal ganglia structures was the
only effective treatment of Parkinson’s disease before the L-
Dopa era. Such surgery virtually stopped once L-Dopa was
widely used because it was superior and has less side effects.
As the progression of the disease despite L-Dopa became clin-
ically apparent, pallidotomy and deep brain stimulation have
become an important rescue measure providing several years
of symptom relief. The new surgical procedures were made
possible by advances in computerized tomography and mag-
netic resonance imaging–based stereotaxic methods and the
availability of pacemaker technology. It is reasonable that ad-
vances in cellular biology and physiology will lead to retrials
of other treatments that have been sidelined. For example, the
transplantation of human fetal dopamine cells initially looked
promising. Experience over many years showed that some
patients had excellent responses and others did not. (This is
very similar to the GDNF trials.) Transplants stopped when a
prominent controlled trial showed relatively little long-term
clinical improvement and that some patients who improved
developed difficult to control dyskinesias, presumably due to
too much dopamine. With the knowledge from 30 years of
clinical trials and the likelihood that earlier intervention is
needed, a new transplant study is being performed on mildly
affected Parkinson’s patients (Barker and TRANSEURO
consortium 2019). This is intended to set the groundwork
for dopamine-producing cells derived from human pluripotent
stem cells. Clearly, the ability to produce such dopamine cells
from a patient’s own stem cell in the future will reopen the
possible effective use of transplantation (Pfisterer et al. 2011).
Likewise, use of cells to deliver GDNF family ligands may
expand if such cells can be protected from dying in situ.
Coatings and encapsulation have been tried for protecting
cells, but so far with little long-term success. However, new
neural engineering encapsulation methods as well as more
robust cell types are now being investigated (Lindvall and
Wahlberg 2008). It is a definite possibility that better results
will come from newly designed cell types producing a modi-
fied neurotrophic which diffuses well in the extracellular
space. Since only nanogram quantities of neurotrophins are
needed, small amounts of correctly designed molecules could
have a clinically significant effect once the biological prob-
lems of protecting the cells and having them survive and se-
crete are overcome.
Finally, alternate delivery routes are being investigated that
enable molecules to get through or around the blood-brain
barrier to sites in the brain. Nasal delivery using GDNF en-
capsulated in a chitosan-coated nanostructured lipid carrier
has been shown to improve behavioral as well as histological
recovery in a rat model of Parkinson’s disease (Gartziandia
et al. 2016). Systemic delivery employing homing peptides
has recently been explored. These are interesting peptides
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which could potentially direct therapeutics and imaging
agents to targeted tissues in the body and through the blood-
brain barrier to specific regions in the brain (Mann et al. 2017).
The fact that exercise is useful in treating the symptoms of
Parkinson’s disease (Fisher et al. 2013) suggests that some
endogenous molecule released from muscle activity pene-
trates the blood-brain barrier to change the brain’s pathophys-
iology. An increase in BDNF in the brain after exercise indi-
cates that neurotrophic factors may be involved in this im-
provement (Mitchell et al. 2010). Current studies are testing
whether exercise can actually slow the progression of the
disease.
Conclusions
Taken together, GDNF family ligands have not yet been fully
perfected and problems of biological activity, dosage, distribu-
tion, and the method of delivery need to be carefully
reevaluated. New trials have to be designed to find the optimal
dosage and be able to follow patients long enough and with the
right protocols to separate symptomatic relief from a disease-
modifying effect. These are difficult tasks but are warranted
because of strong signs in animal and clinical studies that indi-
cate biologically effects which could well be useful in treating
this increasingly prevalent and debilitating, deadly disease.
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